FMC secures $400m investment from Tessenderlo Group
FMC Corporation has secured a $400 million minority equity investment from Tessenderlo Group at $13.30 per share, granting the investor a 20.0% stake. The proceeds will be used to reduce debt by approximately $1 billion, marking the end of FMC's strategic options review. The transaction is subject to regulatory approvals.

*this image is generated using AI for illustrative purposes only.
FMC Corporation has entered into a definitive agreement for Tessenderlo Group to make a strategic minority equity investment of approximately $400 million at a price of $13.30 per share. This transaction will allow Tessenderlo Group to own approximately 20.0% of the outstanding shares of FMC common stock. FMC intends to use the funds to pay down debt, enabling the company to reach its approximately $1 billion debt paydown target and improve its financial flexibility.
The agreement concludes the FMC Board of Directors' exploration of strategic options announced in February 2026. Pierre Brondeau, chairman, chief executive officer and president of FMC, stated that the Board is confident this agreement is the best path forward for the company and its shareholders. The company will continue to execute its operational and strategic plan as an independent entity, focusing on advancing its R&D pipeline and accelerating the commercialization of innovations.
Luc Tack, chief executive officer of Tessenderlo Group, said the investment aligns with the group's strategy to expand its agro platform through cornerstone minority positions in high-quality companies. He cited FMC's long-term potential driven by a new generation of proprietary molecules that are renewing its portfolio.
Strategic and Financial Actions
In addition to the equity investment, FMC has undertaken several measures over recent months to unlock capital and sharpen its strategic focus. These actions include:
- Amending its Revolving Credit Facility to achieve significant covenant relief.
- Raising $1.2 billion in a secured high-yield bond offering.
- Signing an agreement to sell the Company's India commercial business for $252 million.
- Entering into a strategic supply and license agreement with Corteva, Inc., which includes an initial prepayment of $200 million.
- Signing a framework agreement for a $114 million sale & leaseback of its Newark, Delaware property.
Transaction Details
| Transaction Component | Details |
|---|---|
| Investment Amount | Approximately $400 million |
| Price Per Share | $13.30 |
| Ownership Stake | Approximately 20.0% |
| Debt Paydown Target | Approximately $1 billion |
The closing of the transaction is subject to customary conditions, including the receipt of regulatory approvals. BofA Securities and Goldman Sachs & Co. LLC are serving as financial advisors to FMC Corporation, with Davis Polk & Wardwell LLP as legal counsel. Stibbe BV/SRL and Sullivan & Cromwell LLP are serving as legal advisors to Tessenderlo Group.
How will the 20% ownership stake by Tessenderlo Group influence FMC's future strategic decision-making and board composition?
What specific R&D projects in the new proprietary molecule pipeline will be prioritized following the debt paydown?
Will FMC pursue further asset sales or divestitures to maintain financial flexibility after the India commercial business sale?



























